You are here

IMMUNOGLOBULIN COATINGS TO PREVENT CATHETER INFECTION

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: AI40752-01A1
Agency Tracking Number: 39675
Amount: $100,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1997
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
520 HUNTMAR PARK DR, STE 101, Herndon, VA, 20170
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 GRISTINA, ANTHONY G
 () -
Business Contact
Phone: (703) 318-1027
Research Institution
N/A
Abstract
Catheters are one of the most commonly used biomaterial implants, (200 million annually in the U.S.). In long term use as for vascular central lines, the urinary tract and peritoneal dialysis, catheters are particularly susceptible to infection. These infections are resistant to antibiotic treatment and persist until removal of the device. Utilizing the concept of Passive Local Immunotherapy, (PLI), we have demonstrated in animal models that biomaterial associated bacterial infections can be prevented through the direct local application of Human immunoglobulin, (IgG), natural antibodies, to biomaterial surfaces. Immunoglobulins in situ opsonize bacteria on arrival or shortly thereafter. Bacteria are identified and targeted for neutrophil and macrophage phagocytosis and killing while bacteria numbers are low and before they can propagate, release toxins, destroy tissue and form protective biofilms. IgG. also neutralizes bacterial toxins. The objective of this study is to demonstrate the efficacy in vitro and in vivo of local IgG coatings to catheter materials in blocking adhesion, colonization and biofilm type infection by clinically relevant strains of S. epidermidis and P. aetuginosa. The IgG prophylaxis/therapeutic is known to be safe (viral inactivated and FDA approved for i.v.use). Advantages of IgG coatings over current treatments are broad spectrum efficacy,independent of antibiotic resistance mechanisms (e.g. methicillin and vancomycin resistant Staphylococci), and cost- effectiveness.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government